Peripheral arterial occlusive disease: Magnetic resonance imaging and the role of aggressive medical management

World Journal of Surgery

Volumn 31, Issue 4, 2007, Pages 695-704

  Lumsden, Alan B ^a,b   Rice, Terry W ^a   Chen, Changyi ^b   Zhou, Wei ^b   Lin, Peter H ^b   Bray, Paul ^a   Morrisett, Joel ^a   Nambi, Vijay ^a   Ballantyne, Christie ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b MICHAEL E DEBAKEY VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CILOSTAZOL; CLOFIBRATE; CLOPIDOGREL; COLESTIPOL; COLESTYRAMINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; EZETIMIBE; FLUINDOSTATIN; FOLIC ACID; HOMOCYSTEINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LIPID; MEVINOLIN; NICOTINIC ACID; PENTOXIFYLLINE; PRAVASTATIN; PROBUCOL; RAMIPRIL; SIMVASTATIN;

APHERESIS; ATHEROSCLEROSIS; CONFERENCE PAPER; CORONARY ARTERY DISEASE; DISEASE COURSE; EXERCISE; FEMORAL ARTERY; HUMAN; HYPERLIPIDEMIA; ILEUM BYPASS; INFLAMMATION; INTERMITTENT CLAUDICATION; KINESIOTHERAPY; NUCLEAR MAGNETIC RESONANCE IMAGING; PERIPHERAL OCCLUSIVE ARTERY DISEASE; RESTENOSIS; REVASCULARIZATION; STENT; THROMBOCYTE FUNCTION; THROMBOSIS; VASCULAR LESION;

ADRENERGIC BETA-ANTAGONISTS; ALGORITHMS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ARTERIAL OCCLUSIVE DISEASES; ATHEROSCLEROSIS; CLINICAL TRIALS; DISEASE PROGRESSION; EXERCISE THERAPY; FEMORAL ARTERY; HUMANS; MAGNETIC RESONANCE IMAGING; PERIPHERAL VASCULAR DISEASES; PLATELET AGGREGATION INHIBITORS; RISK FACTORS;

EID: 33947698754     PISSN: 03642313     EISSN: 14322323     Source Type: Journal    
DOI: 10.1007/s00268-006-0732-y     Document Type: Conference Paper

References (54)

1. Criqui MH, Fronek A, Barrett-Connor E, et al. The prevalence of peripheral arterial disease in a defined population. Circulation 1985;71:510-515.
2. Criqui MH, Langer RD, Fronek A, et al. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med 1992;326:381-386.
3. Hiatt WR, Regensteiner JG, Hargarten ME, et al. Benefit of exercise conditioning for patients with peripheral arterial disease. Circulation 1990;81:602-609.
4. Hiatt WR, Wolfel EE, Meier RH, et al. Superiority of treadmill walking exercise versus strength training for patients with peripheral arterial disease. Implications for the mechanism of the training response. Circulation 1994;90:1866-1874.
5. McDermott MM, Mehta S, Ahn H, et al. Atherosclerotic risk factors are less intensively treated in patients with peripheral arterial disease than in patients with coronary artery disease. J Gen Intern Med 1997;12:209-215.
6. Hirsch AT, Criqui MH, Treat-Jacobson D, et al. Peripheral arterial disease detection, awareness, and treatment in primary care. JAMA 2001;286:1317-1324.
7. Rehring TF, Sandhoff BG, Stolcpart RS, et al. Atherosclerotic risk factor control in patients with peripheral arterial disease. J Vasc Surg 2005;41:816-822.
8. Lonn E, Yusuf S, Dzavik V, et al. Effects of ramipril and vitamin E on atherosclerosis: the study to evaluate carotid ultrasound changes in patients treated with ramipril and vitamin E (SECURE). Circulation 2001;103:919-925.
9. Pedersen TR, Kjekshus J, Pyorala K, et al. Effect of simvastatin on ischemic signs and symptoms in the Scandinavian simvastatin survival study (4S). Am J Cardiol 1998;81:333-335.
10. Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet 2002;360:7-22.
11. Smith SC, Blair SN, Bonow RO, et al. AHA/ACC Scientific Statement: AHA/ACC guidelines for preventing heart attack and death in patients with atherosclerotic cardiovascular disease: 2001 update: a statement for healthcare professionals from the American Heart Association and the American College of Cardiology. Circulation 2001;104:1577-1579.
12. Dormandy J, Rutherford RB. Management of peripheral arterial disease (PAD). TASC Working Group. TransAtlantic Inter-Society Consensus (TASC). J Vasc Surg 2000;31:S1-S296.
13. Brown BG, Zhao XQ, Bardsley J, et al. Secondary prevention of heart disease amongst patients with lipid abnormalities: practice and trends in the United States. J Intern Med 1997;241:283-294.
14. Ballantyne CM. Clinical trial endpoints: angiograms, events, and plaque instability. Am J Cardiol 1998;82:(6A):5M-11M.
15. Brown BG, Zhao XQ, Chait A, et al. Simvastatin and niacin, antioxidant vitamins, or the combination for the prevention of coronary disease. N Engl J Med 2001;345:1583-1592.
16. LaRosa JC, He J, Vupputuri S. Effect of statins on risk of coronary disease: a meta-analysis of randomized controlled trials. JAMA 1999;282:2340-2346.
17. Khan F, Litchfield SJ, Belch JJ. Cutaneous microvascular responses are improved after cholesterol-lowering in patients with peripheral arterial disease and hypercholesterolaemia. Adv Exp Med Biol 1997;428:49-54.
18. Kirk G, McLaren M, Muir AH, et al. Decrease in P-selectin levels in patients with hypercholesterolaemia and peripheral arterial occlusive disease after lipid-lowering treatment. Vasc Med 1999;4:23-26.
19. Leng GC, Price JF, Jepson RG. Lipid-lowering for lower limb atherosclerosis (Cochrane review). In The Cochrane Library. Oxford, England: Update Software, 2001.
20. Blankenhorn DH, Azen SP, Crawford DW, et al. Effects of colestipol-niacin therapy on human femoral atherosclerosis. Circulation 1991;83:438-447.
21. Lewis B. Randomised controlled trial of the treatment of hyperlipidaemia on progression of atherosclerosis. Acta Med Scand Suppl 1985;701:53-57.
22. Kroon AA, van Asten WN, Stalenhoef AF. Effect of apheresis of low-density lipoprotein on peripheral vascular disease in hypercholesterolemic patients with coronary artery disease. Ann Intern Med 1996;125:945-954.
23. Buchwald H, Bourdages HR, Campos CT, et al. Impact of cholesterol reduction on peripheral arterial disease in the Program on the Surgical Control of the Hyperlipidemias (POSCH). Surgery 1996;120:672-679.
24. Pedersen TR, Kjekshus J, Pyorala K, et al. Effect of simvastatin on ischemic signs and symptoms in the Scandinavian Simvastatin Survival Study (4S). Am J Cardiol 1998;81:333-335.
25. Ansell BJ, Watson KE, Fogelman AM. An evidence-based assessment of NCEP Adult Treatment Panel II guidelines: National Cholesterol Education Program. JAMA 1999;282:2051-2057.
26. Elam MB, Hunninghake DB, Davis KB, et al. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: a randomized trial. JAMA 2000;284:1263-1270.
27. Nissen SE. Effect of intensive lipid lowering on progression of coronary atherosclerosis: evidence for an early benefit from the Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) trial. Am J Cardiol 2005;96:(5A):61F-68F.
28. Collins R, Baigent C, Sandercock P, et al. Antiplatelet therapy for thromboprophylaxis: the need for careful consideration of the evidence from randomised trials. Antiplatelet Trialists' Collaboration. BMJ 1994;309:1215-1217.
29. Collaborative overview of randomised trials of antiplatelet therapy - I: prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. BMJ 1994;308:81-106.
30. Durand-Zaleski I, Bertrand M. The value of clopidogrel versus aspirin in reducing atherothrombotic events: the CAPRIE study. Pharmacoeconomics 2004;22:(suppl 4):19-27.
31. Undas A, Brummel KE, Musial J, et al. Simvastatin depresses blood clotting by inhibiting activation of prothrombin, factor V, and factor XIII and by enhancing factor Va inactivation. Circulation 2001;103:2248-2253.
32. Davi G, Averna M, Novo S, et al. Effects of synvinolin on platelet aggregation and thromboxane B2 synthesis in type IIa hypercholesterolemic patients. Atherosclerosis 1989;79:79-83.
33. Notarbartolo A, Davi G, Averna M, et al. Inhibition of thromboxane biosynthesis and platelet function by simvastatin in type IIa hypercholesterolemia. Arterioscler Thromb Vasc Biol 1995;15:247-251.
34. 2+ and membrane dynamics in patients with primary hypercholesterolemia: effects of pravastatin. Arterioscler Thromb Vasc Biol 1995;15:759-764.
35. Ostergren J, Sleight P, Dagenais G, et al. Impact of ramipril in patients with evidence of clinical or subclinical peripheral arterial disease. Eur Heart J 2004;25:17-24.
36. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000;342:145-153.
37. Teo KK, Yusuf S, Furberg CD. Effects of prophylactic antiarrhythmic drug therapy in acute myocardial infarction. An overview of results from randomized controlled trials. JAMA 1993;270:1589-1595.
38. Aronow WS, Ahn C. Effect of beta blockers on incidence of new coronary events in older persons with prior myocardial infarction and symptomatic peripheral arterial disease. Am J Cardiol 2001;87:1284-1286.
39. National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation 2002;106:3143-3421.
40. Liem A, Reynierse-Buitenwerf GH, Zwinderman AH, et al. Secondary prevention with folic acid: effects on clinical outcomes. J Am Coll Cardiol 2003;41:2105-2113.
41. Currie IC, Wilson YG, Scott J, et al. Homocysteine: an independent risk factor for the failure of vascular intervention. Br J Surg 1996;83:1238-1241.
42. Clarke R, Daly L, Robinson K, et al. Hyperhomocysteinemia: an independent risk factor for vascular disease. N Engl J Med 1991;324:1149-1155.
43. Ridker PM, Rifai N, Pfeffer MA, et al. Long-term effects of pravastatin on plasma concentration of C-reactive protein: the Cholesterol and Recurrent Events (CARE) Investigators. Circulation 1999;100:230-235.
44. Dawson DL, Cutler BS, Hiatt WR, et al. A comparison of cilostazol and pentoxifylline for treating intermittent claudication. Am J Med 2000;109:523-530.
45. Liu Y, Shakur Y, Yoshitake M, et al. Cilostazol (pletal): a dual inhibitor of cyclic nucleotide phosphodiesterase type 3 and adenosine uptake. Cardiovasc Drug Rev 2001;19:369-386.
46. Dawson DL, Cutler BS, Meissner MH, et al. Cilostazol has beneficial effects in treatment of intermittent claudication: results from a multicenter, randomized, prospective, double-blind trial. Circulation 1998;98:678-686.
47. Leng GC, Fowler B, Ernst E. Exercise for intermittent claudication. Cochrane Database Syst Rev 2000;:(2):CD000990.
48. Ernst EE, Matrai A. Intermittent claudication, exercise, and blood rheology. Circulation 1987;76:1110-1114.
49. Wilson SE, Wolf GL, Cross AP. Percutaneous transluminal angioplasty versus operation for peripheral arteriosclerosis: report of a prospective randomized trial in a selected group of patients. J Vasc Surg 1989;9:1-9.
50. Wolf GL, Wilson SE, Cross AP, et al. Surgery or balloon angioplasty for peripheral vascular disease: a randomized clinical trial. Principal investigators and their Associates of Veterans Administration Cooperative Study Number 199. J Vasc Intervent Radiol 1993;4:639-648.
51. Holm J, Arfvidsson B, Jivegard L, et al. Chronic lower limb ischaemia: a prospective randomised controlled study comparing the 1-year results of vascular surgery and percutaneous transluminal angioplasty (PTA). Eur J Vasc Surg 1991;5:517-522.
52. Keller PJ, Drayer BP, Fram EK, et al. MR angiography with two-dimensional acquisition and three-dimensional display. Radiology 1989;173:527-532.
53. Laub G, Kaiser W. MR angiography with gradient motion refocusing. J Comput Assist Tomog 1988;12:377-382.
54. Lenz GW, Haacke EM, Masaryk TJ, et al. In-plane vascular imaging: pulse sequence design and strategy. Radiology 1988;166:875-882.